Transgene Sa Reports Revenue Results for the Third Quarter and Nine Months Ended September 30, 2018; Provides Cash Burn Guidance for the Year 2018
Transgene confirms that it expects 2018 cash burn to be around 25 million based on the current development plan. The financial visibility is confirmed until September 2019 and does not take into account the potential monetization of the Tasly Biopharmaceuticals shares ($48 million), which could extend the cash runway.